Keith Graham (@Graham_KAN) profile picture

Brit in MedChem @ Boehringer-Ingelheim. Tweets = personal opinion

Berlin, Germany
Joined December 2018
Photo by Keith Graham (@Graham_KAN)Photo by Keith Graham (@Graham_KAN)
Keith Graham retweeted
Our Next #MedChemCASES is coming !! and it s a joint event with the @YoungSciNet . The webinar will be followed by a round table discussing the life as foreign scientist in Germany !! Register here : us06web.zoom.us/webinar/regi… #webinar #medchem #research
1
13
1
22
First day of my new adventure at Boehringer-Ingelheim completed! Strange to start a new job remotely, was interesting! Looking forward to learning loads and meeting new colleagues!
15
After 17 years on campus, today is my last day - very strange feeling!! Will miss a lot of friends and colleagues! Would like to thank Nuvisan ICB, Bayer and Schering for believing in me!! New adventure starts Jan 2021!
3
1
16
Keith Graham retweeted
First disclosure !!!!! Do you want to learn more about our AhR antagonist currently in Phase 1 ? Check Norbert’s talk next week at the virtual EFMC Program : efmc-ismc-virtual.org/speake… #NuvisanICB @EuroMedChem @BayerPharma #immunooncology
6
15
And I was there!🤩👍😊
3️⃣5️⃣ years ago today - one of the greatest in our history! 🙌 We beat Sunderland 1-0 at Wembley to lift the 1985 League Cup! 🏆
1
After careful consideration for the safety of our members, the local community and our staff, ACS has decided to terminate the ACS Spring 2020 National Meeting in Philadelphia (#ACSPhilly). Please visit the meeting web page for complete details: ow.ly/FrEr50yH15p
21
561
161
716
One happy fan!!! Great season!😀 OTBC!!
THAT. IS. IT. WE ARE GOING UP! 😁 #ncfc
Proud to have been part of a great team effort! Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction pnas.org/content/early/2019/…
1
RAS genes are major oncogenes but have generally been considered undruggable. Check out our latest paper: A dual approach (FBS+HTS) supported by x-ray and biophysics generated selective nM compounds for SOS1 (activator of RAS). lnkd.in/eTcZGPt
5
5
Targeting Ras, the nemesis of cancer drug discovery. A new paper by my colleagues @BayerPharma is showcasing the beauty of lead design: Hybridizing a hit from a fragment screen with a HTS lead series gives the potent probe BAY-293: @EvotecAG @PNASNews pnas.org/content/early/2019/…
13
37